Last checked at 5 Feb 2021 12:56
UK watchdog confirms continued 'high' safety of Covid-19 vaccines
(Sharecast News) - Ongoing safety checks by the UK regulator confirmed the safety of Covid-19 vaccines.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades5,418
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
10,822.00
Bid:
10,820.00
Ask:
10,824.00
Change:
-92.00 (-0.84%)
Spread:
4.00 (0.037%)
Open:
10,914.00
High:
10,934.00
Low:
10,764.00
Prev. Close:
10,914.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.5 Feb 2021 12:42
UPDATE 2-Seven million Italians seen fully vaccinated by end-March - COVID commissioner
(Adds details, context)By Emilio ParodiMILAN, Feb 5 (Reuters) - If vaccine supplies are confirmed, seven million Italians could be fully vaccinated against COVID-19 by the end of March, the government's special commissioner Domenico Arcuri said on...
Read more5 Feb 2021 12:42
UPDATE 1-Seven million Italians could be fully vaccinated by end-March - COVID commissioner
(Adds details)MILAN, Feb 5 (Reuters) - If vaccine supplies will be confirmed, seven million Italians could be fully vaccinated against COVID-19 by the end of the March, the government's special commissioner Domenico Arcuri said on Friday.Arcuri sa...
Read more5 Feb 2021 11:45
UPDATE 2-UK regulators say extra AstraZeneca vaccine data highlights efficacy in elderly
(Adds Oxford on UK variant)LONDON, Feb 5 (Reuters) - British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines off...
Read more5 Feb 2021 11:45
UPDATE 1-UK regulators say extra AstraZeneca vaccine data highlights efficacy in elderly
(Adds extra detail, quotes)LONDON, Feb 5 (Reuters) - British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines off...
Read more5 Feb 2021 11:00
UK regulators say extra AstraZeneca vaccine data highlights efficacy in elderly
LONDON, Feb 5 (Reuters) - British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on FridayBritain...
Read more5 Feb 2021 11:00
UK regulator says data from Pfizer, AstraZeneca vaccine rollout confirms safety
LONDON, Feb 5 (Reuters) - Britain's medicine regulator on Friday said that data from the first weeks of the rollout of Pfizer and AstraZeneca COVID-19 vaccines confirmed their good safety profiles, saying both shots met strict regulatory standard...
Read more5 Feb 2021 10:48
Seven million Italians could be fully vaccinated by end-March - COVID commissioner
MILAN, Feb 5 (Reuters) - If vaccine supplies will be confirmed, seven million Italians could be fully vaccinated against COVID-19 by the end of the March, the government's special commissioner Domenico Arcuri said on Friday.Arcuri said the first 2...
Read more5 Feb 2021 10:35
AstraZeneca Files Virus Vaccine For Approval In Japan
AstraZeneca Files Virus Vaccine For Approval In Japan
Read more5 Feb 2021 09:21
UPDATE 2-Best week in 3 months for UK mid-caps as Aggreko jumps on buyout offer
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Aggreko tops mid-caps* Insurer Beazley up after reassuring on 2021 profitability* Retailer French Connection surges on takeover talks* FTSE...
Read more5 Feb 2021 08:05
AstraZeneca's Imfinzi fails to meet endpoint in cancer trial
(Sharecast News) - AstraZeneca said on Friday that its Imfinzi (durvalumab) drug failed to meet its primary endpoint in a Phase III trial for head and neck cancers.
Read more5 Feb 2021 07:55
UPDATE 1-AstraZeneca's Imfinzi drug fails in head and neck cancer trial
(Adds details on trial, product sales)Feb 5 (Reuters) - AstraZeneca said on Friday its Imfinzi drug did not prolong survival in a trial testing it as an initial treatment of head and neck cancer, a setback in its push to widen use of the immunothe...
Read more5 Feb 2021 06:00
INSIGHT-Countdown to 'catastrophe:' Inside Europe's fight for COVID shots
By Francesco Guarascio and John ChalmersBRUSSELS, Feb 5 (Reuters) - In a meeting last week in the Europa building in Brussels, home of the European Union's political leadership, diplomats for the 27 member states were desperate.The EU had paid bil...
Read more4 Feb 2021 19:54
UPDATE 2-Canada to shrug off 'momentary disruptions' in vaccine supply, working closely with U.S. - Trudeau
(Recasts with comments by Prime Minister Trudeau)By Steve Scherer and Allison MartellOTTAWA, Feb 4 (Reuters) - Canada will succeed in inoculating its population despite "momentary disruptions" in the supply of COVID-19 vaccines and is working close...
Read more4 Feb 2021 19:54
UPDATE 1-AstraZeneca's COVID-19 shots may arrive in Canada before end March -minister
(Adds Canadian officials on vaccine rollout)TORONTO/OTTAWA, Feb 4 (Reuters) - Deliveries of AstraZeneca Plc's COVID-19 vaccine to Canada could begin before the end of March, if the country's health regulator approves its use, federal procurement m...
Read more